ESR1 and neoplasm: A more recent study demonstrated that, upon activation with E2 and fulvestrant, an ER inhibitor, GPER1, also stimulates the proliferation of lung carcinoma cells and tumor growth via EGFR–ERK1/2 signaling pathway (3).